MARKET

ARTL

ARTL

Artelo Biosciences Inc
NASDAQ
1.270
-0.020
-1.55%
After Hours: 1.260 -0.01 -0.79% 19:31 06/17 EDT
OPEN
1.310
PREV CLOSE
1.290
HIGH
1.330
LOW
1.200
VOLUME
220.04K
TURNOVER
--
52 WEEK HIGH
85.80
52 WEEK LOW
1.190
MARKET CAP
4.43M
P/E (TTM)
-0.0326
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ARTL last week (0608-0612)?
Weekly Report · 2d ago
Artelo Biosciences Presents Metabolite Identification And Profiling Data From Its FABP Inhibitor Candidate ART26.12; Tracks Three Metabolites From Plasma Of Healthy Volunteers Given Single 900 Mg Oral Dose Of ART26.12
Benzinga · 06/10 11:40
Artelo Biosciences reports favorable human metabolite profile for ART26.12 in completed SAD trial
PUBT · 06/10 11:38
Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success
Barchart · 06/10 06:38
Weekly Report: what happened at ARTL last week (0601-0605)?
Weekly Report · 06/08 09:43
Weekly Report: what happened at ARTL last week (0525-0529)?
Weekly Report · 06/01 09:45
Artelo Biosciences Launches Flexible At-The-Market Offering
TipRanks · 05/27 21:37
Crude Oil Falls Over 5%; Dycom Industries Shares Surge Following Q1 Results
Benzinga · 05/27 18:31
More
About ARTL
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of therapeutics that modulate lipid-signaling pathways. The Company is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.

Webull offers Artelo Biosciences Inc stock information, including NASDAQ: ARTL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARTL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARTL stock methods without spending real money on the virtual paper trading platform.